Kitazawa T, Matsumoto K, Fujita S, Seto K, Hasegawa T
Department of Social Medicine, Toho University School of Medicine, Tokyo, Japan.
Department of Social Medicine, Toho University School of Medicine, Tokyo, Japan.
Transplant Proc. 2017 Jan-Feb;49(1):4-9. doi: 10.1016/j.transproceed.2016.10.007.
When assessing the cost of transplants in Japan, earlier studies have been limited to case series that investigated inpatient cost alone. Few studies have evaluated total cost, which includes inpatient, outpatient, and pharmaceutical costs, or compared costs before and after transplantation. Using the National Database of Health Insurance Claims and Specific Health Checkups of Japan (NDB), we investigated the total cost of major transplantation and contributing factors.
We analyzed the cost and complications of patients who underwent a cadaveric renal transplantation (CRT), living renal transplantation (LRT), living-donor liver transplantation (LDLT), allogeneic bone marrow transplantation, autologous bone marrow transplantation, allogeneic peripheral blood stem cell transplantation, or autologous peripheral blood stem cell transplantation (auto-PBSCT) from April 2009 to March 2010.
The highest total cost of the month of transplantation was 4.95 million yen (JPY) for LDLT. Among renal transplantations, the cost of CRT was higher than LRT (3.69 vs 3.55 million JPY). Recipients of auto-PBSCT complicated by graft-versus-host disease, urinary tract infection, sepsis, or pneumonia had a significantly higher average total cost during the month of transplantation and the 2 following months than patients without it, as well as statistically longer total treatment days.
In Japan, almost all medical services are covered by national health insurance, and the Japan government has begun to allow the use of the NDB for research activities. This is the first study to use the NDB to analyze the cost of transplantation, with technical and institutional limitations.
在评估日本移植手术的成本时,早期研究仅限于仅调查住院成本的病例系列。很少有研究评估包括住院、门诊和药物成本在内的总成本,或比较移植前后的成本。我们使用日本全国健康保险索赔和特定健康检查数据库(NDB),调查了主要移植手术的总成本及影响因素。
我们分析了2009年4月至2010年3月期间接受尸体肾移植(CRT)、活体肾移植(LRT)、活体供肝移植(LDLT)、同种异体骨髓移植、自体骨髓移植、同种异体外周血干细胞移植或自体外周血干细胞移植(auto-PBSCT)的患者的成本和并发症。
移植当月总成本最高的是LDLT,为495万日元。在肾移植中,CRT的成本高于LRT(369万日元对355万日元)。auto-PBSCT患者若并发移植物抗宿主病、尿路感染、败血症或肺炎,其移植当月及随后两个月的平均总成本显著高于未并发的患者,且总治疗天数在统计学上更长。
在日本,几乎所有医疗服务都由国民健康保险覆盖,日本政府已开始允许使用NDB进行研究活动。这是第一项使用NDB分析移植成本的研究,存在技术和制度上的局限性。